ArticleNucleic acids research2025
A cancer persistent DNA repair circuit driven by MDM2, MDM4 (MDMX), and mutant p53 for recruitment of MDC1 and 53BP1 on chromatin.
Article in Nucleic acids research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Harnessing MDM2-Mediated Targeted Degradation of Transcriptional and Epigenetic Machinery to Disrupt Oncogenic Addictions in Pediatric Sarcoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- MDM4 promotes chemoresistance in bladder cancer by attenuating P53-mediated EMT.Translational andrology and urology · 2026Article
- Article
- Mutant p53 Directs PARP to Regulate Replication Stress and Drive Breast Cancer Metastasis.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
- Update of
Authors and funding
9 authors.
Funding
Abstract
DNA damage signaling requires functional interactions between 53BP1 and the wild-type p53 tumor suppressor. Cancer cells often express elevated levels of transcriptionally inactive mutant p53 (mtp53) that maintains MDM2 and MDMX (MDM4) binding partners. The ability of mtp53 to functionally interact with additional proteins in the context of a dynamic equilibrium with MDM2-MDMX heterodimers has not been described. Employing a stable isotope labeling in cell culture analysis in T47D breast cancer cells (expressing mtp53 L194F), we uncovered several chromatin-associated DNA replication and repair factors as MDM2-regulated phosphoproteins, including 53BP1. We used proximity ligation analysis in multiple breast cancer cell lines to confirm 53BP1-MDM2 complex formation. We demonstrated that a mtp53-MDM2/MDMX complex promoted 53BP1-MDC1 interactions by showing that mtp53-MDM2/MDMX complex disruptors, Nutlin 3a and ALRN-6924, reduced the 53BP1-MDC1 nuclear interactions (especially in S-phase). Surprisingly, these MDM2-driven MDC1-53BP1 interactions were not ATM dependent, suggesting distinct 53BP1-MDC1 complexes in response to genotoxic stress. We found that MDM2-deficient cells have increased poly-ADP-ribosylation on chromatin which supports the possibility that a mtp53-MDM2/MDMX pathway promotes aberrant DNA repair. Taken together, our data suggest that a mtp53-MDM2/MDMX complex orchestrates DNA repair machinery activity on chromatin, thus priming cancer cells for persistent DNA damage repair (CPR).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.